Cosmos Health Projects $22.7M Annual Revenue from Four New US Products, Dwarfing Market Cap
COSM is trading near its 52-week low of $0.195 (7.0% above the low) on elevated volume (4.1× avg).
Summary
Cosmos Health announced the introduction of four new '18 Series' nutraceutical products in the US, projecting over $22.7 million in annualized revenue and approximately $17.0 million in gross profit. This update consolidates and expands on previous individual product announcements, with the total projected revenue significantly exceeding the company's current market capitalization. The news is highly material given the company's recent going concern warnings and its active $100 million ATM offering, as these projections could substantially improve its financial outlook and path to profitability.
At the time of this announcement, COSM was trading at $0.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $0.20 to $1.32. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.